Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639028 | 0.76 | HRH3 (0.40) | HRH3CCR2KCNH2 | |
| SCHEMBL24498748 | 0.76 | HRH3 (0.49) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL22016512 | 0.71 | HRH3 (0.48) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL23102841 | 0.69 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL23103966 | 0.69 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL23107070 | 0.69 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL23114664 | 0.68 | CHRM2 (0.34) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23107140 | 0.68 | CHRM2 (0.34) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL23103974 | 0.68 | CHRM2 (0.34) | HRH3CHRM2HTR1ADRD3HTR2B | |
| SCHEMBL21157892 | 0.68 | HRH3 (0.45) | HRH3CCR2KCNH2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030867-B2 | Hsp90β selective inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030867-B2 | Hsp90β selective inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | HRH3 4270/4885CCR2 3854/4885KCNH2 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.